Low Back Pain - Pipeline Review, H2 2015 Is Released

Low Back Pain - Pipeline Review, H2 2015 Summary Global Markets Direct s, Low Back Pain - Pipeline
Review, H2 2015, provides an overview of the Low Back Pains therapeutic pipeline. This report provides
comprehensive information on the therapeutic development for Low Back Pain, complete with
comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news
and press releases. It also reviews key players involved in the therapeutic development for Low Back
Pain and special features on late-stage and discontinued projects. Global Markets Directs report
features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Low Back Pain - The report reviews key
pipeline products under drug profile section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental activities - The report reviews key players
involved in the therapeutics development for Low Back Pain and enlists all their major and minor
projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the
Low Back Pain products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources - Pipeline products coverage based on
various stages of development ranging from pre-registration till discovery and undisclosed stages - A
detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Low
Back Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news
and deals relating related to pipeline products Reasons to buy - Provides strategically significant
competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas
of leading companies - Identify and understand important and diverse types of therapeutics under
development for Low Back Pain - Plan mergers and acquisitions effectively by identifying key players of
the most promising pipeline - Devise corrective measures for pipeline projects by understanding Low
Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and
expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.

with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173378/low-backpain-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173378/low-back-pain-pipeline-review-h2-2015

Table of Contents

Introduction 7
Global Markets Direct Report Coverage 7
Low Back Pain Overview 8
Therapeutics Development 9
Pipeline Products for Low Back Pain - Overview 9
Low Back Pain - Therapeutics under Development by Companies 10
Low Back Pain - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Low Back Pain - Products under Development by Companies 15
Low Back Pain - Companies Involved in Therapeutics Development 16
Adynxx, Inc. 16
Aestus Therapeutics, Inc. 17
Astellas Pharma Inc. 18
Eli Lilly and Company 19
Frontier Biotechnologies Co., Ltd 20
Grunenthal GmbH 21
Hisamitsu Pharmaceutical Co., Inc. 22
Immune Pharmaceuticals Inc. 23
Ipsen S.A. 24
MEDRx Co., Ltd. 25
2

Mesoblast Limited 26
Nektar Therapeutics 27
Orion Oyj 28
Pacira Pharmaceuticals, Inc. 29
Pfizer Inc. 30
Stayble Therapeutics 31
Low Back Pain - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(acetaminophen + tramadol hydrochloride) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(etodolac + lidocaine) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46

AB-001 - Drug Profile 48

Product Description 48
Mechanism of Action 48
R&D Progress 48
abobotulinumtoxin A - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ASP-7962 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ATX-09002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AYX-2 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
bupivacaine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
cebranopadol - Drug Profile 57
Product Description 57
Mechanism of Action 57
4

R&D Progress 57
dexmedetomidine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Drug for Chronic Low Back Pain - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
duloxetine hydrochloride DR - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HP-3150 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
lidocaine hydrochloride - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MPC-06ID - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NKTR-181 - Drug Profile 69

Product Description 69
Mechanism of Action 69
R&D Progress 69
tanezumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
zoledronic acid - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Low Back Pain - Recent Pipeline Updates 74
Low Back Pain - Dormant Projects 87
Low Back Pain - Discontinued Products 88
Low Back Pain - Product Development Milestones 89
Featured News & Press Releases 89
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with
Chronic Low Back Pain 89
Jan 23, 2014: Pfizer Reports Top-Line Results from ALO-02 Phase 3 Study 90
Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity for Cymbalta 90
Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study 90
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92

Contact Us 92
Disclaimer 93

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173378/low-back-painpipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects